Eli Lilly is ending its collaboration with Foghorn Therapeutics on a synthetic lethality program and cutting Foghorn’s headcount by about 40%, according to reporting on the partnership unwind. The companies are dropping the Phase program described as part of the synthetic lethality effort, reflecting how strategic reprioritization can follow clinical or preclinical uncertainty. The development supports a broader pattern of consolidation and cost control that many biotechs are applying as pipeline and competition pressures rise. Foghorn’s reduction indicates that even modality-forward collaborations can shrink quickly when scientific strategy and internal resource allocation no longer align with expected timelines or risk. Sector relevance is high: partnering strategy is increasingly tied to rapid evidence milestones, and workforce reductions at smaller innovators can directly influence how quickly candidates move toward future partnering or new internal programs.